Welcome to the international HTA database

Showing [21919 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	Medical Services Advisory Committee (MSAC)	Review of MBS Items for specific ophthalmology services under the MBS Quality Framework Stage 1
2009	Health Services Assessment Collaboration (HSAC)	Review of national and international clinical practice guidelines for the management of Borderline Personality Disorder: a systematic review.
2024	Health Information and Quality Authority (HIQA)	Review of national rare disease strategies in selected countries
2002	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	Review of non-randomised mammographic screening programmes - Systematic review
1997	Australian Health Technology Advisory Committee (AHTAC)	Review of nucleic acid amplification technology
1997	Australian Health Technology Advisory Committee (AHTAC)	Review of nucleic acid amplification technology - systematic review
2003	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Review of primary care interventions to improve the quality of chronic disease management. IPE-03/39 (Public report)
2021	Health Information and Quality Authority (HIQA)	Review of processes in use to inform the expansion of newborn bloodspot screening programmes
2004	New Zealand Health Technology Assessment (NZHTA)	Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer
2006	New Zealand Health Technology Assessment (NZHTA)	Review of the National Cervical Screening programme. Chapter 5: interim operational policy and quality standards 2000. Technical brief.
1995	University of York	Review of the research on the effectiveness of health service interventions to reduce variations in health
1996	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Review of the scientific evidence of commercial products based on electromagnetic fields
1998	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Review of the scientific evidence of the clinical and economic implications of resistance of enterococcus to vancomycin
2009	Agency for Healthcare Research and Quality (AHRQ)	Reviews of selected pharmacogenetic tests for non-cancer and cancer conditions
2014	HAYES, Inc.	Revisional surgery for treatment of complications after bariatric surgery
2022	Agency for Care Effectiveness (ACE)	Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Revivent™ for heart failure with left ventricular scar
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Reza Band® for laryngopharyngeal reflux
2021	Malaysian Health Technology Assessment (MaHTAS)	Rezūm therapy for management of benign prostatic hyperplasia
2000	Alberta Heritage Foundation for Medical Research (AHFMR)	RF tonsillar ablation
2010	NIHR Horizon Scanning Centre (NIHR HSC)	RG7204 for BRAF V600E mutation positive metastatic malignant melanoma - first or second line
2016	NIHR Horizon Scanning Centre (NIHR HSC)	RGN-259 for neurotrophic keratopathy
2008	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review
2015	Institute of Health Economics (IHE)	Rheumatoid arthritis in a policy perspective: a registry for research and better treatment of Albertans
2010	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	RhinoChill intra-nasal cooling system
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Rhinochill intranasal cooling device for protective cooling the brain after a cerebral ischaemic event
2015	NIHR Horizon Scanning Centre (NIHR HSC)	rhNGF for neurotrophic keratitis – first line
2016	NIHR Horizon Scanning Centre (NIHR HSC)	rhPTH (Natpar) for hypoparathyroidism – adjunctive therapy
2010	Institute for Clinical and Economic Review (ICER)	Rhythm control and stroke prevention strategies for patients with atrial fibrillation
2003	Institute for Clinical Systems Improvement (ICSI)	Rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation
2015	NIHR Horizon Scanning Centre (NIHR HSC)	RhythmView™ system for cardiac arrhythmias
1999	Scottish Health Purchasing Information Centre (SHPIC)	Ribavirin and interferon alfa in chronic hepatitis C - an update
2002	Scottish Health Purchasing Information Centre (SHPIC)	Ribavirin and interferon alfa in the treatment of chronic hepatitis C
2000	University HealthSystem Consortium (UHC)	Ribavirin/interferon alfa 2b
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib for advanced hormone receptor positive, HER2 negative breast cancer – first line
2017	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib with tamoxifen and goserelin, or a non-steroidal aromatase inhibitor and goserelin - breast cancer: advanced; hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative; premenopausal women – first line
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Ridaforolimus for unresectable locally advanced and metastatic soft tissue and bone sarcoma - maintenance therapy
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Rifaximin (Xifaxanta®)
2019	Agency for Care Effectiveness (ACE)	Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2015	NIHR Health Services and Delivery Research programme	Right cot, right place, right time: improving the design and organisation of neonatal care networks – a computer simulation study
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Rigosertib for higher risk myelodysplastic syndromes – second and subsequent line
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Rilonacept for cryopyrin associated periodic syndromes
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Rilonacept for gout
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Rilpivirine (Edurant®)
1997	Wessex Institute for Health Research and Development (WIHRD)	Riluzole for motor neurone disease
1996	Scottish Health Purchasing Information Centre (SHPIC)	Riluzole for motor neurone disease. Briefing note
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Riluzole for the treatment of amyotryophic lateral sclerosis: an assessment of clinical efficacy and safety
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Rimonabant (Acomplia) for type 2 diabetes
2004	NIHR Horizon Scanning Centre (NIHR HSC)	Rimonabant for smoking cessation, weight loss and cardiovascular risk factors of overweight/obesity - horizon scanning review
2007	National Institute for Health and Care Excellence (NICE)	Rimonabant for the treatment of overweight and obese patients (withdrawn)
2009	NIHR Health Technology Assessment programme	Rimonabant for the treatment of overweight and obese people
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Rindopepimut for EGFRvIII positive glioblastoma multiforme - first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Riociguat (Adempas — Bayer HealthCare) indication: chronic thromboembolic pulmonary hypertension
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Riociguat (Adempas®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Riociguat (Adempas®)
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Riociguat for the treatment of pulmonary hypertension
2013	NIHR Health Technology Assessment programme	Risk Adjustment In Neurocritical care (RAIN) - prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study
2007	Andalusian Health Technology Assessment Area (AETSA)	Risk adjustment systems in health services assessment
2001	Health Council of the Netherlands Gezondheidsraad (GR)	Risk assessment of DON (deoxynivanol) in grain products - systematic review, expert panel
1995	Health Council of the Netherlands Gezondheidsraad (GR)	Risk assessment of manual lifting
2008	Institute of Health Economics (IHE)	Risk assessment tools for predicting recidivism of spousal violence
2014	Agency for Healthcare Research and Quality (AHRQ)	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. preventive services task force recommendation
2020	NIHR Health Technology Assessment programme	Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
2007	New Zealand Health Technology Assessment (NZHTA)	Risk factors for breast cancer in women: a systematic review of the literature
2010	Penn Medicine Center for Evidence-based Practice (CEP)	Risk factors for complications of percutaneous coronary intervention
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Risk factors for high resource utilization in patients with sickle cell disease
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Risk factors for hospital readmission
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Risk Factors for Surgical Site Infection and Infection Prevention in Elective Spine Surgery
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Risk factors to consider for extended anticoagulant therapy: a review of guidelines
1996	Health Council of the Netherlands Gezondheidsraad (GR)	Risk is more than just a number
2005	Alberta Heritage Foundation for Medical Research (AHFMR)	Risk management for health technology assessment programs
2015	NIHR Health Services and Delivery Research programme	Risk modelling for quality improvement in the critically ill: making best use of routinely available data
2003	Centre for Clinical Effectiveness (CCE)	Risk of cerebral herniation due to lumbar puncture in children with suspected meningitis
2000	Centre for Clinical Effectiveness (CCE)	Risk of infection in patients with femoral fractures who experience delays in surgery of more than 12 hours
1997	Health Council of the Netherlands Gezondheidsraad (GR)	Risk profiles for HIV-positive individuals
2018	NIHR Health Technology Assessment programme	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2020	NIHR Health Technology Assessment programme	Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT
2013	HAYES, Inc.	Risk-reducing (prophylactic) mastectomy
2021	NIHR Public Health Research (PHR) programme	RISKIT-CJS Pragmatic randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a multi-component intervention to reduce substance use and risk-behaviour in adolescents engaged with the criminal justice system
2021	NIHR Health Technology Assessment programme	Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study
2016	NIHR Health Technology Assessment programme	Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records
2013	The HTA Center of the Stockholm County Council/Gotland	Risks associated with planned home delivery for nulliparous women
2005	Health Council of the Netherlands Gezondheidsraad (GR)	Risks of alcohol consumption related to conception, pregnancy and breastfeeding
2007	Health Council of the Netherlands Gezondheidsraad (GR)	Risks of exposure to ionising radiation
2000	Health Council of the Netherlands Gezondheidsraad (GR)	Risks of folic acid fortification
1996	Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS)	Risks of occupational anaesthetic gas exposure for the pregnant woman and the fetus - systematic review
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Risperidone long-acting injection (Risperdal Consta) for prevention of recurrent episodes in bipolar 1 disorder
2024	National Institute for Health and Care Excellence (NICE)	Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2009	HAYES, Inc.	Rituxan (Genentech Inc. and Biogen Idec Inc.) for Graft-Versus-Host Disease
2011	HAYES, Inc.	Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for Chronic Lymphocytic Leukemia(CLL)
2010	HAYES, Inc.	Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for multiple sclerosis
2009	HAYES, Inc.	Rituxan (rituximab) (Genentech Inc. and Biogen Idec Inc.) for rheumatoid arthritis refractory to methotrexate and/or tumor necrosis factor (TNF) inhibitors
2010	HAYES, Inc.	Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for systemic lupus erythematosus
2000	Alberta Heritage Foundation for Medical Research (AHFMR)	Rituxan(R) (rituximab)
2004	NIHR Health Technology Assessment programme	Rituximab (MabThera(R)) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Rituximab (MabThera) for chronic lymphocytic leukaemia
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Rituximab (Mabthera) for non-Hodgkin’s lymphoma – first line maintenance therapy